World Cancer-Free 2020 Conference cordially invites researchers, physicians, cancer associations and public healthcare professionals from all over the globe to be present at “New Trends in Cancer Immunotherapy and Immunology" which is going to be held October 19-20, 2020 Vancouver, Canada.
World Cancer-Free 2020 is a platform that permits the dedicated and devoted Cancer professionals in to explore their knowledge, their experience, and their achievements in an advanced way. World Cancer-Free 2020 conference discuss a new and innovative technologies in oncology field has perceived during recent years, which will drive the Oncology community one standard up. New trends and  technologies in cancer is growing so fast these days, permitting researchers,  the capabilities that they had never thought possible even just a few years ago. Now a day, people can expect to experience the very best of what modern-day clinical cancer has to offer. Today, we have many cutting-edge tools in order to deliver even a higher-quality care.

Venue:
Vancouver a bustling west coast seaport in British Columbia is among Canada’s densest, most ethnically diverse cities. A popular filming location, it’s surrounded by mountains, and also has thriving art, theatre, and music scenes. Vancouver Art Gallery is known for its works by regional artists, while the Museum of Anthropology houses preeminent First Nations collections.
Vancouver is the city's urban planning design philosophy. Vancouver is well known as an urban centre surrounded by nature, making tourism its second-largest industry. Major film production studios in Vancouver and nearby Burnaby have turned Greater Vancouver and nearby areas into one of the largest film production centres in North America, earning it the nickname "Hollywood North".

Who Can Attend 

Mode of Participation

Conference Scientific Sessions:

Session 1. Cancer Metabolism and the Control of the Epigenome:
Cancer metabolism refers to the alterations in cellular metabolism pathways that are evident in cancer cells compared with most normal tissue cells. Metabolic alterations in cancer cells are numerous and include aerobic glycolysis, reduced oxidative phosphorylation and the increased generation of biosynthetic intermediates needed for cell growth and proliferation.
Relevant conferences:Cancer Metabolism Conferences | Cancer Metabolism Congress | Cancer Metabolism Meetings | Cancer Metabolism Summits | Metabolism Research | Metabolism scientific Events | Cancer Metabolism Workshops | Cancer Epigenetics  Conferences | Cancer Epigenetics Congress | Epigenetics Meetings | Epigenetics Summits | Cancer Epigenetics Research | Cancer Epigenetics scientific  Events | Cancer Epigenetics Events | Cancer Epigenetics  Workshop

Session 2. Cancer Cell Plasticity and Resistance to Cancer Therapies:
During cancer progression, tumor cells undergo molecular and phenotypic changes collectively referred to as cellular plasticity. Such changes result from microenvironmental cues, stochastic genetic and epigenetic alterations, and/or treatment-imposed selective pressures, thereby contributing to tumor heterogeneity and therapy resistance. Epithelial–mesenchymal plasticity is the best-known case of tumor cell plasticity, but recent work has uncovered other examples, often with functional consequences. In this review, we explore the nature and role(s) of these diverse cellular plasticity programs in premalignant progression, tumor evolution, and adaptation to therapy and consider ways in which targeting plasticity could lead to novel anticancer treatments.
Relevant conferences: Cell Therapy Summit | Onco Cell Therapy Meeting | Gene Therapy Conference | Cancer Therapy Conference | Cancer Therapy Summit | Cancer Therapy Symposium | Stem Cell Conference | Stem Cell Congress  |  Cancer & Therapies workshop  | Oncology scientific Events | 

Session 3. Visualizing Early Cancer in the Tissue Context:
Early identification of high-risk disease could greatly reduce both mortality and morbidity due to oral cancer. We describe a simple handheld device that facilitates the direct visualization of oral-cavity fluorescence for the detection of high-risk precancerous and early cancerous lesions. Blue excitation light is employed to excite green-red fluorescence from fluorophores in the oral tissues. Tissue fluorescence is viewed directly along an optical axis collinear with the axis of excitation to reduce inter- and intraoperator variability. This robust, field-of-view device enables the direct visualization of fluorescence in the context of surrounding normal tissue.
Relevant conferences:Cancer Pathology Conference | Cancer Pathology Congress | Cance Surgical Meeting | Cancer  Pathology Summit | Cancer Surgical Research | Cancer Pathology scientific Events | Cancer Pathology Events  | Cancer  Pathology Workshop

Session 4. Immunotherapy - Opportunities & Challenges:
Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumor types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development.
Relevant conferences:Cancer Immunotherapy Conference | Cancer Immunotherapy Congres | Neuroimmunology Meeting | Neuroimmunology Summit | Cancer Immunotherapy Research | Immunology scientific Events | Immunology Immunotherapy Workshop 

Session 5. New Technologies in Diagnostic Onco-Pathology:
In the past decade, advances in precision oncology have resulted in an increased demand for predictive assays that enable the selection and stratification of patients for treatment. The enormous divergence of signaling and transcriptional networks mediating the crosstalk between cancer, stromal and immune cells complicates the development of functionally relevant biomarkers based on a single gene or protein. However, the result of these complex processes can be uniquely captured in the morphometric features of stained tissue specimens.
Relevant conferences:Onco-Pathology Conference | Onco-Patholog Congress | Surgical Pathology Meeting | Pathology Summits | Onco-Pathology Research | Onco-Pathology Scientific Events | Surgical Events  | Onco-Pathology Workshop | Surgical Scientific Events  

Session 6. Basic Mechanisms of Cell Death:
Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives. Since the field continues to expand and novel mechanisms that orchestrate multiple cell death pathways are unveiled, we propose an updated classification of cell death subroutines focusing on mechanistic and essential (as opposed to correlative and dispensable) aspects of the process.
Relevant conferences: Cell Death Conference | Cell Death Symposium | Cell Biology Meeting | Cell Biology Summit | Biology Conference | Biology Conference Workshop |Cancer Conference | Cancer Congress | Cancer Meeting | Cancer Summit | Cancer Research | Cell Therapy Clinical Trials

Session 7. Tumor Immunology and Microbiota:
Tumor immunology refers to the relationship between immune function and tumor cells, which is crucial for our understanding of the mechanisms of both tumor rejection and tumor progression. The immunological mechanisms involved in cancer growth are highly complex, including tissue-resident and blood-derived cells. The human immune system mounts natural endogenous response to highly immunogenic tumor cells through a series of steps, including the presenting of tumor antigens to T cells via antigen-presenting cells (APCs), priming and activation of T cells in the lymph nodes, trafficking and infiltration of T cells into tumor beds, recognition of cancer cells by T cells, development of antigen-specific effector and memory T cells, and humoral immunity, allowing effector T cells and other endogenous immune cells, as well as tumor-effective antibodies to tumor to eliminate cancer cells.
Relevant conferences:Tumor immunology Conferences | Tumor immunology Congress | Microbiome Meeting | Tumor immunology Summit | Tumor immunology Research | Microbiome scientific Events | Tumor immunology Events | Tumor immunology Workshop | Microbiota Conference | Microbiota Congress | Microbiota Meeting | Microbiota Summit |   Microbiotascientific  Events |  Microbiota Symposium  |  Microbiome Workshop

Session 8. Cancer Pathology and Genetics:
Recent technical advances have brought insights into the biology of cancer in human, establishing it as a disease driven by genetic mutations. Beside inherited family tumor syndromes caused by germline mutations, somatic genetic alterations occur early in tumourigenesis, which accumulate during the progression of the disease and its treatment. Based on these observations, medical oncology has started to enter an era of stratified medicine, where treatment selection is becoming tailored to drugable molecular pathways.
Relevant conferences: Cancer  Pathology Conference | Cancer  Pathology Congres | Cancer genetics conference  | Pathology Meeting | Cancer Genetics Conference | Cancer Genetics Research | Cancer Pathology scientific Events | Cancer Pathology Events  | Cancer  Pathology Workshop | Genetics & Molecular Biology Conference | Genetics & Molecular Biology Symposium

Session 9. DNA Damage Responses:
The DNA damage response is a network of cellular pathways that sense, signal and repair DNA lesions. Surveillance proteins that monitor DNA integrity can activate cell cycle checkpoints and DNA repair pathways in response to DNA damage, to prevent the generation of potentially deleterious mutations.
Relevant conferences:Cancer Conference | Cancer Congress | DNA Repair Conference | DNA  Damage  Conference | DNA Replication Conference | DNA Repair Meeting | DNA  Damage Summit | DNA Replication Symposium

Session 10. Advanced Cancer Research and Treatment:
If you are diagnosed with advanced cancer, or your disease has progressed to this point, you will have a number of issues to talk about with your loved ones and your health care team. You’ll need to discuss future steps and what to expect. Having these talks may not be easy. But knowing your options and sharing them with others will make it easier for you to move forward with your care.
Relevant conferences:Cancer Immunology Conference | Cancer Immunology Congress | Cancer Immunology Meeting | Cancer Immunology Summit | Cancer Immunology Research | Cancer Immunology scientific Events | Cancer Immunology Workshop

Key Topics